Do adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder?

  title={Do adrenergically active drugs have a role in the first-line treatment of attention-deficit/hyperactivity disorder?},
  author={Philip L Hazell},
  journal={Expert Opinion on Pharmacotherapy},
  pages={1989 - 1998}
  • P. Hazell
  • Published 1 October 2005
  • Psychology, Biology, Medicine
  • Expert Opinion on Pharmacotherapy
Adrenergically active drugs used for the treatment of attention-deficit/hyperactivity disorder (ADHD) include the α-agonists, monoamine oxidase inhibitors, tricyclics and the selective noradrenergic re-uptake inhibitors. In addition to a longer duration of treatment effect than the predominantly dopaminergic psychostimulant drugs, a theoretical advantage of the adrenergically active drugs is a lesser tendency to aggravate common comorbidities of ADHD, such as anxiety, obsessionality, depression… 
2 Citations
Chronic Disorders in Children and Adolescents
Chronic disorders in children and adolescents , Chronic disorders in children and adolescents , کتابخانه دیجیتال جندی شاپور اهواز


Non-Stimulant Treatment of Attention-Deficit/Hyperactivity Disorder
Clinical guidelines for each of these agents, as well as their use in combination with stimulants in comorbid conditions, will be discussed.
Novel treatments for attention-deficit/hyperactivity disorder in children.
Atomoxetine, which is being developed for ADHD, reduces symptoms of ADHD without exacerbating comorbid conditions and is associated with only minor side effects, including subtle changes in blood pressure and heart rate.
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
Two studies early in its development confirmed that atomoxetine, a specific and selective inhibitor of noradrenergic uptake, was effective for the treatment of children with ADHD and was found to be well tolerated.
Pharmacological management of attention-deficit hyperactivity disorder
There is a need for additional direct comparisons between the longer-acting agents to effectively guide the practicing clinician in selecting an agent for the treatment of ADHD.
Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial.
Venlafaxine may be a promising agent for the treatment of ADHD in adults and controlled clinical trials are needed to further examine this issue.
New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder
The newly approved resolved enantiomer product d-MPH is now available in an IR formulation, and when administered at one-half the dose to that of the racemate, is purported to produce a longer duration of clinical effect, despite essentially identical pharmacokinetics.
Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
Cardiac effects and effects on weight, height, and metabolism that are related to treatment of ADHD with atomoxetine in children and adolescents are discussed.
Review of New Compounds Available in Australia for the Treatment of Attention-Deficit Hyperactivity Disorder
The newer treatments for ADHD offer advantages over immediate-release methyphenidate in dosing schedule and duration of action that may be of particular benefit to adolescent and adult patients.
The norepinephrine transporter gene and attention-deficit hyperactivity disorder.
The results do not support the NET1 gene as a major genetic susceptibility factor in ADHD.
Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.
This preliminary study showed that tomoxetine was effective in treating adult ADHD and was well tolerated, and these promising results provide support for further studies of tomoxettine over an extended period of treatment.